Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Live-attenuated Yersinia pestis vaccines.

Literature DB >> 23750796

Live-attenuated Yersinia pestis vaccines.

Xiaoyi Wang¹, Xuecan Zhang, Dongsheng Zhou, Ruifu Yang.

Abstract

Plague caused by Yersinia pestis is one of the most dangerous infectious diseases. There is no ideal plague vaccine available for human use, but a number of licensed killed whole-cell and live-attenuated vaccines have been available in the past. Currently, there are a number of vaccines under development, including live-attenuated, DNA and subunit vaccines, among others. This review deals with the development of live-attenuated plague vaccines. Traditionally, live-attenuated plague vaccines have been developed by multiple passages of fully virulent Y. pestis, but they have not gained general acceptance due to safety concerns. Recent attempts to construct attenuated Y. pestis strains with specifically defined mutations have opened the door for developing new candidates for live-attenuated plague vaccines, with a proper balance between safety and protective efficacy.

Entities: Disease Species

Mesh：

Substances：

Year: 2013 PMID： 23750796 DOI： 10.1586/erv.13.42

Source DB: PubMed Journal: Expert Rev Vaccines ISSN： 1476-0584 Impact factor: 5.217

Keyword Cloud
Cited

19 in total

1. LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Authors: Wei Sun; Shilpa Sanapala; Jeremy C Henderson; Shandiin Sam; Joseph Olinzock; M Stephen Trent; Roy Curtiss
Journal: Infect Immun Date: 2014-08-11 Impact factor: 3.441

2. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.

Authors: William Bowen; Lalit Batra; Amanda R Pulsifer; Esma S Yolcu; Matthew B Lawrenz; Haval Shirwan
Journal: Vaccine Date: 2019-08-12 Impact factor: 3.641

3. Yersinia pestis antibiotic resistance: a systematic review.

Authors: Chen Lei; Suresh Kumar
Journal: Osong Public Health Res Perspect Date: 2022-02-18

4. Comparison of virulence between the Yersinia pestis Microtus 201, an avirulent strain to humans, and the vaccine strain EV in rhesus macaques, Macaca mulatta.

Authors: Guang Tian; Zhizhen Qi; Yefeng Qiu; Xiaohong Wu; Qingwen Zhang; Xiaoyan Yang; Youquan Xin; Jian He; Yujing Bi; Qiong Wang; Jiyuan Zhou; Yanxiao Fan; Yazhou Zhou; Yongqiang Jiang; Ruifu Yang; Xiaoyi Wang
Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452

Review 5. Plague: Recognition, Treatment, and Prevention.

Authors: Ruifu Yang
Journal: J Clin Microbiol Date: 2017-12-26 Impact factor: 5.948

Review 6. Rational considerations about development of live attenuated Yersinia pestis vaccines.

Authors: Wei Sun; Roy Curtiss
Journal: Curr Pharm Biotechnol Date: 2013 Impact factor: 2.837

7. YopP-expressing variant of Y. pestis activates a potent innate immune response affording cross-protection against yersiniosis and tularemia [corrected].

Authors: Ayelet Zauberman; Yehuda Flashner; Yinon Levy; Yaron Vagima; Avital Tidhar; Ofer Cohen; Erez Bar-Haim; David Gur; Moshe Aftalion; Gideon Halperin; Avigdor Shafferman; Emanuelle Mamroud
Journal: PLoS One Date: 2013-12-16 Impact factor: 3.240